Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  Koffiekamer  /  In de race voor een Coronavirus Vaccin - wie wint?

Ontvang nu dagelijks onze kooptips!

word abonnee

Koffiekamer« Terug naar discussie overzicht

In de race voor een Coronavirus Vaccin - wie wint?

261 Posts
Pagina: «« 1 2 3 4 5 6 ... 14 »» | Laatste | Omlaag ↓
  4. forum rang 5 MisterBlues 19 mei 2020 08:16
    quote:

    hirshi schreef op 18 mei 2020 20:26:

    [...]

    Dank je.

    Maar als contrarian heb ik mijn handen vol aan langlopende calls Shell die ik jonas geadviseerd heb en zelf ook aangeschaft heb

    Nu gewiekst kort calls afgegeven
    Mooi spel.
    Welke langlopende calls en welke korte? Verklaar je nader, als je wilt?

    Oliemarkt wel interessant maar gevaarlijk door onvoorspelbaar geopolitiek spel. Ik heb plukjes Brent en WTI etf met een hefboom.

    Overigens: volgens mij kan je beter in Galapagos zitten dan in Gilead maar ik zie beide aandelen als een goede belegging. Gilead heeft nog meer in de koker zoals je zegt maar moet ook meer ballen tegelijk ophouden. Daarom is de natuurlijke hefboom van Galapagos veel groter.

    MB
  5. forum rang 5 MisterBlues 19 mei 2020 08:16
    Moderna Reveals ‘Positive’ Data In Coronavirus Vaccine Trial, Markets Spike

    Lisette VoytkoForbes Staff

    I cover breaking news.
    Updated May 18, 2020, 11:19am EDT

    TOPLINE

    Boston biopharmaceutical Moderna announced Monday that “positive” data was collected from an early-stage human trial of a coronavirus vaccine, with all 45 participants producing COVID-19 antibodies?—and markets responded positively in pretrading hours, as the possibility of producing a vaccine against the virus moved one small step closer.
    Cambridge Biotech Moderna Leads in Race For Coronavirus Vaccine

    A Moderna scientist works in the company's lab. David L. Ryan/The Boston Globe via Getty Images
    KEY FACTS

    The trial participants were divided into three groups, with each receiving a different amount of vaccine: 25 micrograms, 100 micrograms and 250 micrograms.

    Each group received two doses by intramuscular injections in their upper arms, with 28 days between doses.

    After 43 days, or two weeks after receiving the second dose, the 25-microgram group showed antibody levels consistent with blood samples from recovered coronavirus patients, according to a Moderna press release.

    The 100-microgram group produced antibodies that “significantly exceeded” levels seen in recovered coronavirus patients.

    At least eight participants (the first four in both the 25-microgram and 100-microgram groups) developed what are called “neutralizing antibodies,” which defend cells from pathogens or infectious particles.

    Markets jumped in response, with futures on the Dow Jones industrial average up over 550 points; the S&P 500 was up over 60 points, and the Nasdaq over 165 before opening bell.
    Crucial quote

    “These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 [micrograms],” Moderna Chief Medical Officer Dr. Tal Zaks said in a statement. “When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials.”
    Big number

    Over 100. That’s how many coronavirus vaccines are in development across the globe, according to the World Health Organization. At least 8 are in human trials.
    What to watch for

    Moderna said it expects to begin a Phase 3 trial of the vaccine in July, as Phase 2?—with 600 participants?—is expected to launch in the near future.
    Key background

    Moderna made its vaccine with mRNA (or “messenger RNA”), a genetic material that contains instructions for cells to make certain proteins. With a coronavirus vaccine, the mRNA could tell a person’s cells to make a COVID-19 protein without them actually getting sick. Other companies like Pfizer PFE are developing coronavirus vaccines using mRNA. It was reported May 12, 2020, that the U.S. Food and Drug Administration fast-tracked Moderna’s vaccine efforts, and the company has received $500 million in federal funding for development. Forbes estimated that Moderna’s CEO, Stéphane Bancel, became a billionaire in early April with a net worth of just over $1 billion.
    Further reading

    Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus (Moderna press release)

    Fueled By $500 Million In Federal Cash, Moderna Races To Make A Billion Doses Of An Unproven Cure (Forbes)

    Moderna CEO Stéphane Bancel Becomes A Billionaire As Stock Jumps On Coronavirus Vaccine News (Forbes)

    FDA ‘Fast Tracks’ First Coronavirus Vaccine From Moderna (Forbes)

    Pfizer Launches U.S. Human Trial Of Coronavirus Vaccine (Forbes)

    Full coverage and live updates on the Coronavirus
  6. forum rang 5 MisterBlues 19 mei 2020 08:42


    THE CHANGING FORTUNES OF THE WORLD’S RICHEST

    Harvard biology professor and serial entrepreneur Timothy Springer saw promise in a fledgling biotech firm a decade ago and made an early investment. Now, primarily as a result of that bet — on a Cambridge, Massachusetts company called Moderna — he’s a billionaire.

    Shares of Moderna, which has a Covid-19 vaccine currently in human clinical trials, rose more than 12% this week, bucking the overall drop in the stock market. That surge has turned Springer into a billionaire: Forbes estimates he is now worth $1 billion based on his 3.5% equity stake in Moderna and stakes in three smaller biotech outfits.

    “My philosophy is investing in what you know, and I’m a scientist at heart. I love discovering things,” Springer, 72, told Forbes. “Many scientists start companies but few are successful. I’m an active investor and also a very rigorous scientist, and that’s why I have a very high batting average.”

    On Tuesday, Moderna announced that the U.S. Food and Drug Administration fast-tracked its Covid-19 vaccine candidate, giving a boost to the firm’s effort to develop the first vaccine for the disease. Moderna was the first company to begin human trials of its vaccine, on March 16 in Seattle, and the company’s shares have nearly tripled in value since the WHO declared Covid-19 a pandemic on March 11. The breakneck growth had already led to one other Moderna billionaire — CEO Stéphane Bancel, now worth an estimated $2.1 billion.

    Besides moonlighting as a billionaire biotech investor, Springer is a professor of biological chemistry and molecular pharmacology at Harvard Medical School, where he began teaching in 1977 and currently mentors post-doctoral students in his lab. In his research as an immunologist at Harvard, Springer discovered lymphocyte function-associated molecules, which led to the development of several FDA-approved antibody-based drugs. His first foray into entrepreneurship came in 1993 when he founded the biotech outfit LeukoSite, which he took public in 1998 and sold to Millennium Pharmaceuticals a year later in a deal worth $635 million; Springer got about $100 million of that in Millennium shares.

    Springer was a founding investor of Moderna in 2010, when he put about $5 million into the company. Now, a decade later, that initial investment is worth nearly $870 million. But long before Covid-19 had emerged onto the scene, Springer was already thinking about how the company’s groundbreaking mRNA technology could help in the development of vaccines.

    “We had the idea very early on that it could be used for pandemic readiness,” says Springer. “That’s why we invested in doing human trials with different influenza types, the types that are not normally seen in epidemics but could emerge and start a new pandemic. We were aware of this kind of scenario all along.”

    While Moderna may be Springer’s most high-profile bet, he’s also a leading investor in three smaller publicly traded biotech upstarts: Selecta Biosciences, Scholar Rock and Morphic Therapeutic. In the cases of Scholar Rock and Morphic, Springer is also a cofounder, helping build the companies out of his scientific research at Harvard.

    Unfazed by his newfound wealth, Springer still rides his bike to work every day in Cambridge, Massachusetts, where he conducts research at his lab. His only luxury, Springer says, is his home. "I like gardening and collecting rocks...I don’t need the money. I have an academic lifestyle."

    He’s also using his fortune to give back to the scientific community: In 2017, he donated $10 million to establish the Institute for Protein Innovation, an independent nonprofit dedicated to researching protein science and helping biotech entrepreneurs realize their ideas.
  7. forum rang 5 MisterBlues 19 mei 2020 08:45
    “I like active investing, but I also very much like active philanthropy,” says Springer. “My motivation behind [the Institute] is not only to help develop new reliable antibodies that scientists around the world can use for biological discovery, but also, it has new technology that will just allow many more discoveries to be made. It’s the type of science that is difficult to do otherwise in academia.”

    The Harvard professor isn’t the only member of the three-comma-club whose wealth has been boosted by the battle against Covid-19. Some healthcare billionaires’ fortunes have risen by billions of dollars since the WHO declared a global pandemic on March 11. The biotech rally could keep gathering pace as the public eagerly awaits new developments in the fight against Covid-19.

    For his part, Springer is optimistic that the biotech sector will continue its rapid growth even once the pandemic is gone. “Before, we were vilified as charging too much for drugs...but now, everybody is quite aware that biotech is coming to the rescue,” says Springer. “Biotech holds great promise for new drugs, and the faith in biotech is justified.”
    Follow me on Twitter or LinkedIn. Send me a secure tip.

    Giacomo Tognini
  8. Cézan 19 mei 2020 09:12
    Kijk meestal CNN (soms) , deze keer eens BBC World News gevolgd, niet weggezapt en zag de CEO van Moderna van Gilead aan het woord. Men is al bezig met een positief klinkend hoopgevend early trial.

    We wachten af. Of USA of UK. Fransen mss, woord met de franse slag niet voor niets uitgevonden..;)

  10. [verwijderd] 19 mei 2020 23:19
    A Covid-19 Vaccine Could Be Worth Billions for Moderna and Its Rivals

    May 19, 2020 11:39 am ET

    Fresh on the heels of the first data from human tests of its Covid-19 vaccine, Moderna sold $1.3 billion worth of stock on Monday at a price of $76 a share. That’s a fourfold rise from price where the biotech’s stock started the year, and a market value of $30 billion for a company that has yet to sell its first product.

    What investors are betting on, for Moderna (ticker: MRNA) and others developing vaccines against the SARS-CoV-2 virus, is that a third of the developed world’s population will get vaccinated every year. That could amount to a $10 billion annual business, at an estimated price of $30 per vaccination. At higher prices, Covid vaccine revenue would be bigger still.

    On a Monday conference call, Moderna CEO Stéphane Bancel said the Cambridge, Mass., company had not yet decided on a price , in the event that their mRNA-1273 vaccine proves effective in the Phase 2 and 3 trials it will run this year. He said that Moderna was thinking about what Covid-19 illness costs the health-care system.

    Covid’s cost obviously goes beyond the hospital, and it’s already been gigantic . In the U.S. alone, nearly 90,000 have died in a few months’ time. The scale of the coronavirus’ impact explains why there’s such a range of estimates on Wall Street for what vaccine makers will charge. Morgan Stanley analysts this past weekend suggested that pricing might start at $5 to $10 a dose during this first pandemic crisis, then rise to a range of $13 to $30 for preventive doses in future years.

    But at BMO Capital Markets, analyst George Farmer speculated that Moderna could start charging $125 per treatment in the U.S. market and raise that price over time to $200. Most of the world’s health-care systems are government-run, so Farmer’s model assumes that pricing abroad will be a fraction of America’s generous pricing.

    Vaccinations will likely consist of a first shot and then a booster one month later. After clinical trials answer the first crucial question of whether vaccine candidates like Moderna’s prevent Covid in humans, the next question will be how long immunity lasts. Assuming somewhat less mutability than is the case with the flu virus, researchers are guessing that people might need a SARS-CoV-2 vaccination every few years. That’s how analysts like BMO’s Farmer arrive at a count of roughly a third of the population needing a vaccination per year.

    The U.S. population could rise from about 330 million today to more than 360 million by the decade’s end, depending on a bunch of social and economic factors, such as future immigration levels. Different age groups will get vaccinated at differing rates—hopefully unimpeded by antivaccination sentiments. BMO estimates that will work out to about 30% of America’s head count getting vaccinated each year, or some 100 million treatments a year by the second half of this decade. Put a price from $30 to $130 on those numbers, and you get $3 billion to $13 billion in U.S. sales.

    Global sales are harder to forecast, with prices and vaccination rates likely to vary widely throughout the developed and developing countries. BMO’s Farmer guesstimates that sales in the developed world will amount to half or two-thirds the dollar levels of the U.S. Poorer nations will only be able to chip in around 5%. Still, he sees Covid vaccines exceeding $30 billion in sales by the end of the decade. That market size emboldened him to raise his price target on Moderna stock to $112 from $83, after yesterday’s encouraging news on the first handful of patients in Moderna’s Phase 1 trial.

    Even if Moderna’s vaccine becomes the first one available—perhaps this fall, for front-line workers—it won’t be the only one. Pfizer (PFE) and its partner BioNTech (BNTX) are also in the clinic with a vaccine that uses technology similar to Moderna’s. And other vaccine approaches are being tested by the likes of Johnson & Johnson (JNJ) and the vaccine market incumbents Sanofi (SNY) and GlaxoSmithKline (GSK).

    So there will be competition for pricing and market share. That’s good for us customers, but not bad for investors in companies like Moderna. We hate to say it, but the Covid-19 outbreak may not be the last of its kind.

    www.barrons.com/articles/a-covid-19-v...
  12. forum rang 5 MisterBlues 20 mei 2020 08:56
    quote:

    hosternokke schreef op 19 mei 2020 23:42:

    Uh oh...

    BIOTECH
    Vaccine experts say Moderna didn’t produce data critical to assessing Covid-19 vaccine
    By HELEN BRANSWELL @HelenBranswellMAY 19, 2020
    www.statnews.com/2020/05/19/vaccine-e...
    Ik ben benieuwd naar het verweer van Moderna...
  13. forum rang 5 MisterBlues 20 mei 2020 08:57

    Scrutiny of Moderna Announcement Sinks Stocks. Why the Market Is So Sensitive to Vaccine News.

    By Josh Nathan-Kazis
    May 19, 2020 4:49 pm ET

    Order Reprints
    Print Article

    Text size
    An article by Stat reporter Helen Branswell makes a compelling argument for caution on the Moderna vaccine program.
    Photograph by JOSEPH PREZIOSO/AFP via Getty Images

    Markets stumbled just before 3 p.m. on Tuesday, with the Dow Jones Industrial Average falling nearly two hundred points in 10 minutes. The drop came after the health-care news site Stat published an article throwing cold water on Monday’s press release from the biotech company Moderna announcing positive data on its experimental Covid-19 vaccine.

    The Stat report, written by the website’s infectious disease reporter Helen Branswell, who has been one of the best journalists on the Covid-19 beat, wasn’t exactly a scoop. But it did make a compelling argument for caution on the Moderna (ticker: MRNA) vaccine program, quoting vaccine experts who complained about the lack of data in the Monday announcement.

    That Moderna’s release was thin on details would have been clear to investors following closely on Monday. But the sharp market reaction to the Stat report comes a day after an even sharper reaction to the initial Moderna statement, and underlines one essential fact about investing in the second quarter of 2020: Investors have an itchy trigger-finger when it comes to news about Covid-19 vaccines and therapeutics.

    Over and over again in recent weeks, investors have shown a willingness to move the entire market on Covid-19 drug and vaccine news, even when the news is preliminary.

    It’s a point that Barron’s made in our cover story this past weekend, where we noted that the S&P 500 climbed 2.7% one day in April after Gilead Sciences (GILD) announced that a trial run by the National Institute of Allergy and Infectious Diseases had found that its antiviral remdesivir benefited Covid-19 patients, even though the benefit was very small.

    It is also worth noting that Stat’s strong reporting on the crisis has driven a number of these dramatic reactions, including a scoop in April that previewed the remdesivir data.

    On Monday, it happened again , this time over an NIAID trial of Moderna’s Covid-19 vaccine. The data seemed positive, but came from a Phase 1 trial with 45 participants.

    The key news highlighted by the company was that in the first eight people whose samples they had tested, the level of neutralizing antibodies was similar to the levels seen in people who had been sickened by Covid-19 and then recovered.

    It was good news by any measure for investors eager for an end to Covid-19. But it was also interim data on a Phase 1 trial, which is rather early in the game in terms of the normal course of drug development. And as Branswell pointed out in Stat, there was no actual data in the release.

    Moderna shares rose 20% Monday, while the S&P 500 rose 3.2%. Shares of Moderna fell after the close, after the company announced a proposed public offering of $1.3 billion in shares , and was down roughly 5% much of the day Tuesday.

    Just before 3 p.m., as the Stat article went online, shares fell from $73.67 to as low as $70.32. The stock was trading at $72.78 at 3:45 p.m., down 9% on the day.
  14. forum rang 6 haas 20 mei 2020 09:17
    quote:

    haas schreef op 4 mei 2020 23:05:

    [...]

    Beste Mr Blues

    I

    PS mss iets van farma:)
    - ik zit in IBAB(mss asml-tje in haar branche?),
    - Ontex(pampers:) en
    - SDGR (reeds eerder elders genoemd als koopkandidaat op 30 euro, nu 48+

    ad Ontex: is gestart met hoogwaardiege beschermingsprodukten zoals kapjes voor de Chirurgen etc.
    blijft ook doorgaan met maandverband, pampers met/zonder (plas)goten etc
    ad SDGR : staat nu op 66 $
  15. forum rang 5 MisterBlues 20 mei 2020 09:42
    Dit soort berichten gaan we nog veel lezen. Het is al vaker gezegd: het is heel moeilijk een goed vaccin te maken en er zullen vele producenten afvallen.

    Beloftevol ‘apenvaccin’ uit Oxford stelt teleur, spotlight zwaait naar Amerikaans bedrijf Moderna

    Maarten Keulemans 19 mei 2020 17u09 Bron: De Volkskrant

    Tweet

    In een laboratorium van Sinovac Biotech in Beijing waar ze op zoek zijn naar een covid-19-vaccin bekijkt een onderzoeker cellen uit de nieren van een aap.
    AFP In een laboratorium van Sinovac Biotech in Beijing waar ze op zoek zijn naar een covid-19-vaccin bekijkt een onderzoeker cellen uit de nieren van een aap.
    Medisch Een bejubeld kandidaat-vaccin tegen corona uit Oxford blijkt bij nader inzien toch niet zo lekker te werken. Maakt het vaccin van het Amerikaanse bedrijf Moderna meer kans?
  16. forum rang 5 MisterBlues 20 mei 2020 10:29
    quote:

    haas schreef op 20 mei 2020 09:17:

    [...]
    ad Ontex: is gestart met hoogwaardiege beschermingsprodukten zoals kapjes voor de Chirurgen etc.
    blijft ook doorgaan met maandverband, pampers met/zonder (plas)goten etc
    ad SDGR : staat nu op 66 $

    Ontex is sinds het dieptepunt al met 20% gestegen deze lente, er is niet zoveel upside meer.

    Bijna iedereen maakt beschermingsmiddelen tegenwoordig. Zelfs matrassenfabrikant Beter Bed.

    Eerder genoemde biotech Cytodyn nog steeds interessant. Inmiddels gaat Mexico een proef starten, ten gunste van het kandidaat-medicijn Leronlimab, boven Remdesivir!

    Misschien wordt Leronlimab de kurk waar de wereld op gaat drijven!
  17. forum rang 5 MisterBlues 21 mei 2020 07:46
    Pfizer ook nog steeds serieus bezig, uiteraard. Vooral de CEO ervan maakt zich sterk. Er is het geld en het netwerk van Pfizer en de biotech van de Duitse vaccin-specialist BioNtech. Zelfde techniek als Moderna: messengerRNA (mRNA).

    Shot of Hope. Volunteers receive injections of Pfizer’s experimental Covid-19 vaccine in early May at the University of Maryland School of Medicine in Baltimore.

    University of Maryland School of Medicine

    For Bourla, 58, the last four months have been a rollercoaster, an unending series of setbacks and victories. Pfizer is not alone in the race. Most of the world’s biggest pharmaceutical companies, including Johnson & Johnson, Sanofi, AstraZeneca and Roche, are throwing everything they can at Covid-19.
    Some experts feel Bourla’s timeline—a viable vaccine in a matter of a few months—is simply unrealistic. Undeterred, Bourla has tasked hundreds of researchers to scour Pfizer’s trove of experimental and existing medicines to look for potential therapies. Early on, he openly authorized having discussions and sharing proprietary information with rival firms, moves unheard of in the secretive world of big pharma. Bourla has made Pfizer’s manufacturing capabilities available to small biotech concerns and is in talks as well to make large quantities of other companies’ Covid-19 drug candidates.

    Pfizer’s most prominent effort is its work with Mainz, Germany–based BioNTech, an innovative $120 million (2019 sales) outfit that is mostly known for making cancer medications. The resulting experimental Covid-19 vaccine works with messenger RNA, a bleeding-edge technology that has never resulted in a successful treatment. Pfizer is hoping to get emergency-use authorization from the U.S. government for the vaccine by October. Its unique strategy is to rapidly pit four different mRNA vaccine candidates against one another and double down on the most likely winner.
    In preparation, the company is shifting production at four manufacturing plants to make 20 million vaccine doses by the end of the year and hundreds of millions more in 2021. Bourla says Pfizer is willing to spend $1 billion in 2020 to develop and manufacture the vaccine before they know if it will work: “Speed is of paramount importance.”

    While the vaccine effort is getting most of the public’s attention, Pfizer is also rushing to start a clinical trial this summer for a new antiviral drug to treat Covid-19. Additionally, it’s involved in a human study that seeks to repurpose Pfizer’s big arthritis drug, Xeljanz, for later-stage Covid-19 patients.
    “Being the CEO of a pharma company that can make a difference or not in a crisis like this is a very heavy weight,” Bourla says. “Even the way my daughter or son ask me, ‘Do you have something or not?’ Every person who knows me does the same. You feel if you get it right, you can save the world. And if you don’t get it right, you will not.”

    ________________________________________
    In January, Ugur Sahin, the brilliant immunologist who founded BioNTech, read an article about Covid-19 in The Lancet. Sahin built BioNTech to hack human cells to go after diseases, particularly cancer, and he thought similar tech might work against the coronavirus. Soon after, Sahin spoke to Thomas Strüngmann, the German pharma billionaire who for years has backed Sahin and his wife, immunologist Özlem Türeci, in their ventures. “He said, ‘This is a big disaster.’ He said the schools will be closed, that this will be a pandemic,” Strüngmann says, referring to Sahin. “He switched most of his team to the vaccine.”

    A New Reality. Pfizer CEO Albert Bourla under lockdown in his suburban New York home, from which he has directed his troops to “make the impossible possible.”

    Jamel toppin

    In February, Sahin (who is also now a billionaire, as BioNTech’s stock has soared) called up Kathrin Jansen, who heads vaccine research and development for Pfizer. Sahin told Jansen BioNTech had come up with vaccine candidates for Covid-19 and asked if Pfizer would be interested in working with him. “Ugur, you are asking?” Jansen replied. “Of course we are interested.”
    Over the last few years, scientists have become intrigued by the idea of using messenger RNA, the genetic molecule that gives cells protein-making instructions, to develop medicines for cancer, heart disease and even infectious viruses by transforming human cells into drug factories. Because SARS-CoV-2, as the coronavirus is formally known, is an RNA virus, researchers like Sahin focused on the idea of giving mRNA the cellular machinery to make proteins that would create virus-protecting antibodies.

    An mRNA vaccine has huge advantages over a traditional one. Because it can be made directly from the genetic code of the virus, it can be invented and entered into clinical trials in a matter of weeks, rather than months or years. But there’s a big downside: No one has ever successfully made one.
    BioNTech is not alone in pursuing an mRNA vaccine. Moderna Therapeutics, a biotech in Cambridge, Massachusetts, also got going in January and has launched a big human trial for its mRNA vaccine, backed by $483 million from the federal government. Moderna is likewise aiming to produce millions of doses per month by the end of the year.

    Pfizer was already comfortable with BioNTech. Two years ago, the two companies inked a $425 million deal to develop an mRNA flu vaccine. Pfizer was intrigued by the potential of an mRNA approach to short-circuit the process of developing a vaccine for a new strain of the flu every year. That same flexibility and speed appealed to Bourla when it came to working with a partner on a potential vaccine for Covid-19.
    On March 16, Bourla convened Pfizer’s top executives and informed them that return on investment would not play a role in the company’s Covid-19 work. “This is not business as usual,” Bourla told them. “Financial returns should not drive any decisions.”
    ________________________________________
  18. forum rang 5 MisterBlues 21 mei 2020 07:48
    “A billion dollars is not going to break us. And I don’t plan to lose it. I plan to make sure we use this product.”
    ________________________________________
    Pfizer signed a letter of intent with BioNTech the next day. The contract they finalized in April makes no mention of commercialization. Pfizer is bringing its enormous manufacturing, regulatory and research capabilities to the effort. BioNTech is bringing the basic science.
    At the same time, Bourla made the decision to spend $1 billion on the project, so if the vaccine works, it can be made available this autumn. Pfizer will also be on the hook to pay BioNTech an additional $563 million if everything goes according to plan. “A billion dollars is not going to break us. And, by the way, I don’t plan to lose it. I plan to make sure we use this product,” Bourla says. “You never know until you see the data. So yes, we are going to lose a billion if” the vaccine doesn’t work.
    What makes Pfizer’s approach unique is that it’s testing four distinctive vaccines—different mRNA platforms that are supposed to induce a safe immune response. The complex trial will start by testing different dosing levels of the four vaccines in 360 U.S. volunteers and 200 in Germany, eventually expanding to around 8,000 participants.
    The U.S. trial was designed to evolve so the company could quickly stop testing any one of the vaccines if immunogenicity data show it is not producing enough antibodies to confer virus protection. The companies are making adjustments on the fly. BioNTech recently realized one of the vaccine candidates should be dosed at a lower level to be safe—an early fling of a monkey wrench into the plans.
    There is considerable skepticism among experts that Pfizer’s goal of providing millions of doses to vulnerable populations by the fall is possible. Drew Weissmann, whose University of Pennsylvania laboratory has worked with BioNTech on mRNA vaccines for infectious diseases, recently told Forbes it is simply not known if an mRNA vaccine can prevent infectious disease.

    First Time. Ugur Sahin, the Turkish-born CEO of BioNTech. The German outfit was founded 12 years ago, but despite considerable promise it has yet to bring an approved drug to market.
    Andreas Arnold / picture alliance / Getty Images
    Jansen, Pfizer’s vaccine research chief, expects that Pfizer and BioNTech will have a better idea around the beginning of July as to which of the four vaccine candidates is the most promising and whether their hyper-accelerated timeframe is feasible. The company will likely move just one or two of the most promising vaccines to more advanced trials.
    “It’s not easy. As a matter of fact, it has never been done before—I can’t give you a probability,” Jansen says. “An unprecedented crisis, such as the ongoing pandemic, requires unprecedented action. Albert was the first to see that and act on it, and to provide the support and the environment for us to think and act boldly.”
    ________________________________________
  20. forum rang 4 vreemdvermogen 21 mei 2020 11:05
    Het ziet er naar uit dat Oxford deze race niet gaat winnen.

    Vorige maand dacht de gerenommeerde universiteit van Oxford mogelijk al in september de eerste vaccins klaar te hebben. Maar ook de Britse wetenschappers kunnen geen ijzer met handen breken: het vaccin werkt niet.

    Eind april stelden de onderzoekers dat het vaccin werkte bij zes resusaapjes. Uit de technische details die nu zijn gepubliceerd blijkt echter dat de gevaccineerde apen opnieuw besmet kunnen raken. Ook werden er drie kortademig, schrijft de Volkskrant.

    “Het is glashelder dat dit vaccin geen steriele immuniteit geeft, de gouden standaard voor welk vaccin dan ook”, aldus de eminente immunoloog William Haseltine in Forbes. “De viruslading in de neuzen van de gevaccineerde en de niet-gevaccineerde dieren is identiek”, zegt ook de Britse hoogleraar moleculaire virologie Jonathan Ball in The Telegraph. “Dat is van belang. Als dit bij mensen gebeurt, zou het vaccin de verspreiding van het virus niet tegengaan.”

    Toch lijkt het vaccin wel verzachtend te werken. De apen kregen bijvoorbeeld geen longontsteking. Marjolein Kikkert van het LUMC, die werkt aan een vergelijkbaar vaccin, reageert dan ook genuanceerder. “Dit zijn maar weinig apen. En met zulke gemengde uitkomsten heb je er dan eigenlijk niet zoveel aan. Het kan best dat het alsnog prima uitpakt in de menselijke trials.”
261 Posts
Pagina: «« 1 2 3 4 5 6 ... 14 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 865,33 0,00%
EUR/USD 1,0663 -0,08%
FTSE 100 7.863,43 +0,20%
Germany40^ 17.770,70 +0,00%
Gold spot 2.391,45 +1,29%
NY-Nasdaq Composite 15.683,37 -1,15%

Stijgers

VIVORY...
+8,30%
JUST E...
+4,54%
Air Fr...
+3,80%
Alfen ...
+3,41%
Vastned
+1,83%

Dalers

Pharming
-8,64%
PostNL
-5,84%
ASMI
-5,38%
Avantium
-4,26%
BESI
-2,60%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!